Pharmaceutical Investing Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Pharmaceutical Investing Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX for Injection
Pharmaceutical Investing Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Pharmaceutical Investing Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX for Injection
